{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T12:10:26Z","timestamp":1781871026805,"version":"3.54.5"},"reference-count":37,"publisher":"Walter de Gruyter GmbH","issue":"1","license":[{"start":{"date-parts":[[2023,12,27]],"date-time":"2023-12-27T00:00:00Z","timestamp":1703635200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,3,30]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec id=\"j_pp-2023-0019_abs_001\">\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>There are limited treatment options and no consensus on the management of advanced rare ovarian malignancies. Rare ovarian malignancies can present with peritoneal metastases (PM), featuring a similar presentation to more common ovarian subtypes. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS\/HIPEC) is an effective treatment for PM of non-gynecologic origin and, recently, epithelial ovarian cancer. We evaluated the feasibility of CRS\/HIPEC in the management of PM from\u00a0rare ovarian malignancies and report postoperative outcomes on these patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_pp-2023-0019_abs_002\">\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A retrospective review of a single center, prospective database (1994\u20132021) was performed to identify patients with rare ovarian malignancies treated with CRS\/HIPEC. Clavien-Dindo 90-day morbidity\/mortality and Kaplan\u2013Meier overall (OS) and progression-free survival (PFS) were analyzed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_pp-2023-0019_abs_003\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Of 44 patients identified, 28 underwent CRS\/HIPEC. Six were aborted due to extensive disease. Histologic subtypes included: clear cell (5\/28, 17.9\u202f%), endometrioid (5\/28, 17.9\u202f%), granulosa cell (3\/28, 10.7\u202f%), low-grade serous (6\/28, 21.4\u202f%), mesonephric (1\/28, 3.6\u202f%), mucinous (6\/28, 21.4\u202f%), and small cell (2\/28, 7.1\u202f%) carcinomas. Eight (28.6\u202f%) patients had primary and 20 (71.4\u202f%) had recurrent disease. Median peritoneal cancer index (PCI) was 21 (IQR: 6\u201329). Complete cytoreduction (&lt;2.5\u202fmm residual disease) was achieved in 27\/28 (96.4\u202f%). Grade III\/IV complications occurred in 9\/28 (32.1\u202f%) with one (3.6\u202f%) mortality. After a median follow-up of 65.8\u00a0months, 20 patients were alive. Five-year OS and PFS were 68.5 and 52.6\u202f%, respectively.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_pp-2023-0019_abs_004\">\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In patients with PM from rare ovarian malignancies, CRS\/HIPEC is feasible and has an acceptable safety profile. Longer follow-up and multicenter trials are needed.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1515\/pp-2023-0019","type":"journal-article","created":{"date-parts":[[2023,12,26]],"date-time":"2023-12-26T10:20:26Z","timestamp":1703586026000},"page":"15-22","source":"Crossref","is-referenced-by-count":6,"title":["Peritoneal metastases from rare ovarian cancer treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS\/HIPEC)"],"prefix":"10.1515","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5065-1416","authenticated-orcid":false,"given":"Luis Felipe","family":"Falla-Zuniga","sequence":"first","affiliation":[{"name":"Surgical Oncology, Institute for Cancer Care at Mercy , Mercy Medical Center , Baltimore , MD , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4132-9489","authenticated-orcid":false,"given":"Armando","family":"Sardi","sequence":"additional","affiliation":[{"name":"Surgical Oncology, Institute for Cancer Care at Mercy , Mercy Medical Center , Baltimore , MD , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3376-3827","authenticated-orcid":false,"given":"Mary Caitlin","family":"King","sequence":"additional","affiliation":[{"name":"Surgical Oncology, Institute for Cancer Care at Mercy , Mercy Medical Center , Baltimore , MD , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1560-9172","authenticated-orcid":false,"given":"Felipe","family":"Lopez-Ramirez","sequence":"additional","affiliation":[{"name":"Surgical Oncology, Institute for Cancer Care at Mercy , Mercy Medical Center , Baltimore , MD , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5877-0521","authenticated-orcid":false,"given":"Philipp","family":"Barakat","sequence":"additional","affiliation":[{"name":"Surgical Oncology, Institute for Cancer Care at Mercy , Mercy Medical Center , Baltimore , MD , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6337-5278","authenticated-orcid":false,"given":"Carol","family":"Nieroda","sequence":"additional","affiliation":[{"name":"Surgical Oncology, Institute for Cancer Care at Mercy , Mercy Medical Center , Baltimore , MD , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0881-3236","authenticated-orcid":false,"given":"Teresa","family":"Diaz-Montes","sequence":"additional","affiliation":[{"name":"Gynecological Oncology, The Lya Segall Ovarian Cancer Institute , Mercy Medical Center , Baltimore , MD , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6151-5660","authenticated-orcid":false,"given":"Vadim","family":"Gushchin","sequence":"additional","affiliation":[{"name":"Surgical Oncology, Institute for Cancer Care at Mercy , Mercy Medical Center , Baltimore , MD , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"374","published-online":{"date-parts":[[2023,12,27]]},"reference":[{"key":"2025120909300619594_j_pp-2023-0019_ref_001","doi-asserted-by":"crossref","unstructured":"Sehouli, J, Senyuva, F, Fotopoulou, C, Neumann, U, Denkert, C, Werner, L, et al.. Intra-abdominal tumor dissemination pattern and surgical outcome in 214 patients with primary ovarian cancer. J Surg Oncol 2009;99:424\u20137. https:\/\/doi.org\/10.1002\/jso.21288.","DOI":"10.1002\/jso.21288"},{"key":"2025120909300619594_j_pp-2023-0019_ref_002","doi-asserted-by":"crossref","unstructured":"Mercier, F, Bakrin, N, Bartlett, DL, Goere, D, Quenet, F, Dumont, F, et al.. Peritoneal carcinomatosis of rare ovarian origin treated by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: a multi-institutional cohort from PSOGI and BIG-RENAPE. Ann Surg Oncol 2018;25:1668\u201375. https:\/\/doi.org\/10.1245\/s10434-018-6464-z.","DOI":"10.1245\/s10434-018-6464-z"},{"key":"2025120909300619594_j_pp-2023-0019_ref_003","doi-asserted-by":"crossref","unstructured":"Gatta, G, Van Der Zwan, JM, Casali, PG, Siesling, S, Dei Tos, AP, Kunkler, I, et al.. Rare cancers are not so rare: the rare cancer burden in Europe. Eur J Cancer 2011;47:2493\u2013511. https:\/\/doi.org\/10.1016\/j.ejca.2011.08.008.","DOI":"10.1016\/j.ejca.2011.08.008"},{"key":"2025120909300619594_j_pp-2023-0019_ref_004","doi-asserted-by":"crossref","unstructured":"Debuquoy, C, Romeo, C, Vanacker, H, Ray-Coquard, I. Rare ovarian tumors: an update on diagnosis and treatment. Int J Gynecol Cancer 2020;30:879\u201387. https:\/\/doi.org\/10.1136\/ijgc-2020-001235.","DOI":"10.1136\/ijgc-2020-001235"},{"key":"2025120909300619594_j_pp-2023-0019_ref_005","doi-asserted-by":"crossref","unstructured":"Ray-Coquard, I, Trama, AL, Seckl, MJ, Fotopoulou, C, Pautier, P, Pignata, S, et al.. Rare ovarian tumours: epidemiology, treatment challenges in and outside a network setting. Eur J Surg Oncol 2019;45:67\u201374. https:\/\/doi.org\/10.1016\/j.ejso.2017.09.025.","DOI":"10.1016\/j.ejso.2017.09.025"},{"key":"2025120909300619594_j_pp-2023-0019_ref_006","doi-asserted-by":"crossref","unstructured":"El Halabi, H, Gushchin, V, Francis, J, Athas, N, MacDonald, R, Nieroda, C, et al.. The role of cytoreductive surgery and heated intraperitoneal chemotherapy (CRS\/HIPEC) in patients with high-grade appendiceal carcinoma and extensive peritoneal carcinomatosis. Ann Surg Oncol 2012;19:110\u20134. https:\/\/doi.org\/10.1245\/s10434-011-1840-y.","DOI":"10.1245\/s10434-011-1840-y"},{"key":"2025120909300619594_j_pp-2023-0019_ref_007","doi-asserted-by":"crossref","unstructured":"Sugarbaker, PH. Update on the management of malignant peritoneal mesothelioma. Transl Lung Cancer Res 2018;7:599\u2013608. https:\/\/doi.org\/10.21037\/tlcr.2018.08.03.","DOI":"10.21037\/tlcr.2018.08.03"},{"key":"2025120909300619594_j_pp-2023-0019_ref_008","doi-asserted-by":"crossref","unstructured":"Babaier, A, Ghatage, P. Mucinous cancer of the ovary: overview and current status. Diagnostics 2020;10:1\u201316. https:\/\/doi.org\/10.3390\/diagnostics10010052.","DOI":"10.3390\/diagnostics10010052"},{"key":"2025120909300619594_j_pp-2023-0019_ref_009","doi-asserted-by":"crossref","unstructured":"Sinukumar, S, Damodaran, D, Ray, M, Prabhu, A, Katdare, N, Vikram, S, et al.. Cytoreductive surgery with or without HIPEC in the management of peritoneal dissemination from rare histological subtypes of ovarian cancer \u2013 a retrospective study by INDEPSO. Indian J Surg Oncol 2022;14:74\u201381. 0123456789. https:\/\/doi.org\/10.1007\/s13193-022-01640-5.","DOI":"10.1007\/s13193-022-01640-5"},{"key":"2025120909300619594_j_pp-2023-0019_ref_010","doi-asserted-by":"crossref","unstructured":"Alaedin, R, Piso, P, Halmy, L, Panczel, I, Nedelcut, D-S, Herold, Z, et al.. Rare histologies and infrequent indications for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Anticancer Res 2022;42:3681\u201392. https:\/\/doi.org\/10.21873\/anticanres.15857.","DOI":"10.21873\/anticanres.15857"},{"key":"2025120909300619594_j_pp-2023-0019_ref_011","doi-asserted-by":"crossref","unstructured":"van Driel, WJ, Koole, SN, Sikorska, K, Schagen van Leeuwen, JH, Schreuder, HWR, Hermans, RHM, et al.. Hyperthermic intraperitoneal chemotherapy in ovarian cancer. N Engl J Med 2018;378:230\u201340. https:\/\/doi.org\/10.1056\/nejmoa1708618.","DOI":"10.1056\/NEJMoa1708618"},{"key":"2025120909300619594_j_pp-2023-0019_ref_012","doi-asserted-by":"crossref","unstructured":"Cobb, LP, Gershenson, DM. Treatment of rare epithelial ovarian tumors. Hematol Oncol Clin North Am [Internet] 2018;32:1011\u201324. https:\/\/doi.org\/10.1016\/j.hoc.2018.07.015.","DOI":"10.1016\/j.hoc.2018.07.015"},{"key":"2025120909300619594_j_pp-2023-0019_ref_013","unstructured":"Shaco-Levy, R, Fukunaga, M, Stewart, CJR. WHO classification of tumours female genital tumours. In: Cree, IA, editor. WHO female genital tumours, 5th ed. Lyon, France: International Agency for Research on Cancer; 2020, vol 4:132\u20133 pp."},{"key":"2025120909300619594_j_pp-2023-0019_ref_014","doi-asserted-by":"crossref","unstructured":"Gershenson, DM, Okamoto, A, Ray-Coquard, I. Management of rare ovarian cancer histologies. J Clin Oncol 2019;37:2406\u201315. https:\/\/doi.org\/10.1200\/jco.18.02419.","DOI":"10.1200\/JCO.18.02419"},{"key":"2025120909300619594_j_pp-2023-0019_ref_015","doi-asserted-by":"crossref","unstructured":"Del Carmen, MG, Birrer, M, Schorge, JO. Carcinosarcoma of the ovary: a review of the literature. Gynecol Oncol [Internet] 2012;125:271\u20137. https:\/\/doi.org\/10.1016\/j.ygyno.2011.12.418.","DOI":"10.1016\/j.ygyno.2011.12.418"},{"key":"2025120909300619594_j_pp-2023-0019_ref_016","doi-asserted-by":"crossref","unstructured":"Lopez-Ramirez, F, Sardi, A, Studeman, K, King, MC, Falla Zuniga, LF, Nikiforchin, A, et al.. Outcomes after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal dissemination from ovarian carcinosarcoma. Eur J Surg Oncol [Internet]. 2023, in press. https:\/\/doi.org\/10.1016\/j.ejso.2023.03.230.","DOI":"10.1016\/j.ejso.2023.03.230"},{"key":"2025120909300619594_j_pp-2023-0019_ref_017","doi-asserted-by":"crossref","unstructured":"Shankar, S, Ledakis, P, El Halabi, H, Gushchin, V, Sardi, A. Neoplasms of the appendix: current treatment guidelines. Hematol Oncol Clin N Am 2012;26:1261\u201390. https:\/\/doi.org\/10.1016\/j.hoc.2012.08.010.","DOI":"10.1016\/j.hoc.2012.08.010"},{"key":"2025120909300619594_j_pp-2023-0019_ref_018","doi-asserted-by":"crossref","unstructured":"Harmon, RL, Sugarbaker, PH. Prognostic indicators in peritoneal carcinomatosis from gastrointestinal cancer. Int Semin Surg Oncol 2005;2:1\u201310. https:\/\/doi.org\/10.1186\/1477-7800-2-3.","DOI":"10.1186\/1477-7800-2-3"},{"key":"2025120909300619594_j_pp-2023-0019_ref_019","doi-asserted-by":"crossref","unstructured":"Roife, D, Powers, BD, Zaidi, MY, Staley, CA, Cloyd, JM, Ahmed, A, et al.. CRS\/HIPEC with major organ resection in peritoneal mesothelioma does not impact major complications or overall survival: a retrospective cohort study of the US HIPEC collaborative. Ann Surg Oncol [Internet] 2020;27:4996\u20135004. https:\/\/doi.org\/10.1245\/s10434-020-09232-9.","DOI":"10.1245\/s10434-020-09232-9"},{"key":"2025120909300619594_j_pp-2023-0019_ref_020","doi-asserted-by":"crossref","unstructured":"Sugarbaker, PH. New standard of care for appendiceal epithelial neoplasms and pseudomyxoma peritonei syndrome? Lancet [Internet]. 2006;7:69\u201376. https:\/\/doi.org\/10.1016\/s1470-2045(05)70539-8,","DOI":"10.1016\/S1470-2045(05)70539-8"},{"key":"2025120909300619594_j_pp-2023-0019_ref_021","unstructured":"Goodman, MD, McPartland, S, Detelich, D, Saif, MW. Chemotherapy for intraperitoneal use: a review of hyperthermic intraperitoneal chemotherapy and early post-operative intraperitoneal chemotherapy. J Gastrointest Oncol 2016;7:45\u201357. https:\/\/doi.org\/10.3978\/j.issn.2078-6891.2015.111."},{"key":"2025120909300619594_j_pp-2023-0019_ref_022","doi-asserted-by":"crossref","unstructured":"Clavien, PA, Barkun, J, De Oliveira, ML, Vauthey, JN, Dindo, D, Schulick, RD, et al.. The clavien-dindo classification of surgical complications: five-year experience. Ann Surg 2009;250:187\u201396. https:\/\/doi.org\/10.1097\/sla.0b013e3181b13ca2.","DOI":"10.1097\/SLA.0b013e3181b13ca2"},{"key":"2025120909300619594_j_pp-2023-0019_ref_023","doi-asserted-by":"crossref","unstructured":"MacKay, HJ, Brady, MF, Oza, AM, Reuss, A, Pujade-Lauraine, E, Swart, AM, et al.. Prognostic relevance of uncommon ovarian histology in women with stage III\/IV epithelial ovarian cancer. Int J Gynecol Cancer 2010;20:945\u201352. https:\/\/doi.org\/10.1111\/igc.0b013e3181dd0110.","DOI":"10.1111\/IGC.0b013e3181dd0110"},{"key":"2025120909300619594_j_pp-2023-0019_ref_024","doi-asserted-by":"crossref","unstructured":"Bristow, RE, Tomacruz, RS, Armstrong, DK, Trimble, EL, Montz, FJ. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol 2002;20:1248\u201359. https:\/\/doi.org\/10.1200\/jco.2002.20.5.1248.","DOI":"10.1200\/JCO.2002.20.5.1248"},{"key":"2025120909300619594_j_pp-2023-0019_ref_025","doi-asserted-by":"crossref","unstructured":"Chang, SJ, Bristow, RE, Ryu, HS. Impact of complete cytoreduction leaving no gross residual disease associated with radical cytoreductive surgical procedures on survival in advanced ovarian cancer. Ann Surg Oncol 2012;19:4059\u201367. https:\/\/doi.org\/10.1245\/s10434-012-2446-8.","DOI":"10.1245\/s10434-012-2446-8"},{"key":"2025120909300619594_j_pp-2023-0019_ref_026","doi-asserted-by":"crossref","unstructured":"Lim, MC, Chang, SJ, Park, B, Yoo, HJ, Yoo, CW, Nam, BH, et al.. Survival after hyperthermic intraperitoneal chemotherapy and primary or interval cytoreductive surgery in ovarian cancer: a randomized clinical trial. JAMA Surg 2022;157:374\u201383. https:\/\/doi.org\/10.1001\/jamasurg.2022.0143.","DOI":"10.1001\/jamasurg.2022.2941"},{"key":"2025120909300619594_j_pp-2023-0019_ref_027","doi-asserted-by":"crossref","unstructured":"Ferrandina, G, Legge, F, Salutari, V, Paglia, A, Testa, A, Scambia, G. Impact of pattern of recurrence on clinical outcome of ovarian cancer patients: clinical considerations. Eur J Cancer 2006;42:2296\u2013302. https:\/\/doi.org\/10.1016\/j.ejca.2006.03.025.","DOI":"10.1016\/j.ejca.2006.03.025"},{"key":"2025120909300619594_j_pp-2023-0019_ref_028","doi-asserted-by":"crossref","unstructured":"Usami, T, Kato, K, Taniguchi, T, Abe, A, Nomura, H, Yamamoto, A, et al.. Recurrence patterns of advanced ovarian, fallopian tube, and peritoneal cancers after complete cytoreduction during interval debulking surgery. Int J Gynecol Cancer 2014;24:991\u20136. https:\/\/doi.org\/10.1097\/igc.0000000000000142.","DOI":"10.1097\/IGC.0000000000000142"},{"key":"2025120909300619594_j_pp-2023-0019_ref_029","doi-asserted-by":"crossref","unstructured":"Sinukumar, S, Damodaran, D, Ray, M, Mehta, S, Paul, L, Bhatt, A. Pattern of recurrence after interval cytoreductive surgery and HIPEC following neoadjuvant chemotherapy in primary advanced stage IIIC\/IVA epithelial ovarian cancer. Eur J Surg Oncol [Internet] 2021;47:1427\u201333. https:\/\/doi.org\/10.1016\/j.ejso.2021.01.013.","DOI":"10.1016\/j.ejso.2021.01.013"},{"key":"2025120909300619594_j_pp-2023-0019_ref_030","doi-asserted-by":"crossref","unstructured":"Chambers, LM, Yao, M, Morton, M, Gruner, M, Chichura, A, Horowitz, M, et al.. Patterns of recurrence in women with advanced and recurrent epithelial ovarian cancer treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Gynecol Oncol [Internet] 2021;161:389\u201395. https:\/\/doi.org\/10.1016\/j.ygyno.2021.01.039.","DOI":"10.1016\/j.ygyno.2021.01.039"},{"key":"2025120909300619594_j_pp-2023-0019_ref_031","doi-asserted-by":"crossref","unstructured":"Ceresoli, M, Verrengia, A, Montori, G, Busci, L, Coccolini, F, Ansaloni, L, et al.. Effect of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy on relapse pattern in primary epithelial ovarian cancer: a propensity score based case-control study. J Gynecol Oncol 2018;29:1\u201310. https:\/\/doi.org\/10.3802\/jgo.2018.29.e53.","DOI":"10.3802\/jgo.2018.29.e53"},{"key":"2025120909300619594_j_pp-2023-0019_ref_032","doi-asserted-by":"crossref","unstructured":"Lee, YJ, Seon, KE, Jung, DC, Lee, JY, Nam, EJ, Kim, SW, et al.. Interval debulking surgery with or without hyperthermic intraperitoneal chemotherapy in advanced-stage ovarian cancer: single-institution cohort study. Front Oncol 2022;12:1\u20138. https:\/\/doi.org\/10.3389\/fonc.2022.936099.","DOI":"10.3389\/fonc.2022.936099"},{"key":"2025120909300619594_j_pp-2023-0019_ref_033","doi-asserted-by":"crossref","unstructured":"Jafari, MD, Halabi, WJ, Stamos, MJ, Nguyen, VQ, Carmichael, JC, Mills, SD, et al.. Surgical outcomes of hyperthermic intraperitoneal chemotherapy: analysis of the American college of surgeons national surgical quality improvement program. JAMA Surg 2014;149:170\u20135. https:\/\/doi.org\/10.1001\/jamasurg.2013.3640.","DOI":"10.1001\/jamasurg.2013.3640"},{"key":"2025120909300619594_j_pp-2023-0019_ref_034","doi-asserted-by":"crossref","unstructured":"Halkia, E, Spiliotis, J, Sugarbaker, P. Diagnosis and management of peritoneal metastases from ovarian cancer. Gastroenterol Res Pract 2012;2012:541842. https:\/\/doi.org\/10.1155\/2012\/541842.","DOI":"10.1155\/2012\/541842"},{"key":"2025120909300619594_j_pp-2023-0019_ref_035","doi-asserted-by":"crossref","unstructured":"Chi, DS, Eisenhauer, EL, Zivanovic, O, Sonoda, Y, Abu-Rustum, NR, Levine, DA, et al.. Improved progression-free and overall survival in advanced ovarian cancer as a result of a change in surgical paradigm. Gynecol Oncol [Internet] 2009;114:26\u201331. https:\/\/doi.org\/10.1016\/j.ygyno.2009.03.018.","DOI":"10.1016\/j.ygyno.2009.03.018"},{"key":"2025120909300619594_j_pp-2023-0019_ref_036","doi-asserted-by":"crossref","unstructured":"Kuusela, K, Norppa, N, Auranen, A, Saarelainen, S. Maximal surgical effort increases the risk of postoperative complications in the treatment of advanced ovarian cancer. Eur J Surg Oncol [Internet] 2022;48:2525\u201330. https:\/\/doi.org\/10.1016\/j.ejso.2022.06.007.","DOI":"10.1016\/j.ejso.2022.06.007"},{"key":"2025120909300619594_j_pp-2023-0019_ref_037","doi-asserted-by":"crossref","unstructured":"Yee, FZY, Tan, GHC, Chia, CS, Soo, KC, Teo, MCC. Uncommon indications for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Pleura Peritoneum 2017;2:129\u201336. https:\/\/doi.org\/10.1515\/pp-2017-0017.","DOI":"10.1515\/pp-2017-0017"}],"container-title":["Pleura and Peritoneum"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/pp-2023-0019\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/pp-2023-0019\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T11:06:54Z","timestamp":1765278414000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/pp-2023-0019\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,27]]},"references-count":37,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,2,28]]},"published-print":{"date-parts":[[2024,3,30]]}},"alternative-id":["10.1515\/pp-2023-0019"],"URL":"https:\/\/doi.org\/10.1515\/pp-2023-0019","relation":{},"ISSN":["2364-768X"],"issn-type":[{"value":"2364-768X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,27]]}}}